Efficacy

In pharmacology, efficacy refers to the maximum biological response that a medicine can produce when it binds to its target receptor, regardless of how much medicine is given. It is an intrinsic property of the medicine-receptor interaction, distinct from potency (which describes how much medicine is required to produce a given effect). A highly efficacious medicine can produce a large response; a low-efficacy medicine, even at saturating doses, cannot.

A classic example illustrates the difference. Morphine and codeine are both opioids, but morphine is a full agonist with high intrinsic efficacy at the mu opioid receptor - at sufficient dose, it can produce maximal analgesia. Codeine, on the other hand, has very weak intrinsic activity and relies on being converted in the body to morphine (via CYP2D6) to produce most of its effect. Buprenorphine is a partial agonist; even at very high doses, it produces less maximal effect than morphine, which is why it has a 'ceiling' for respiratory depression and is useful in opioid use disorder treatment.

In clinical research, the term efficacy has a slightly different but related meaning. Clinical efficacy refers to whether a medicine produces the intended therapeutic effect under controlled experimental conditions - randomized trials, ideal patients, careful adherence. This is contrasted with effectiveness, which describes how well the medicine performs in real-world clinical practice, where patients have comorbidities, miss doses, and may receive less rigorous monitoring. A medicine may show high efficacy in a phase 3 trial but lower effectiveness in routine practice - or vice versa.

Clinically, efficacy considerations guide medicine selection. When maximal symptom relief is required and side effects can be tolerated, high-efficacy medicines are chosen - e.g., morphine over codeine for severe cancer pain. When a ceiling on effect is desirable - to reduce overdose risk in opioid use disorder - partial agonists like buprenorphine are preferred. In chronic conditions like rheumatoid arthritis, biologic DMARDs often have higher efficacy than conventional DMARDs but at greater cost and infection risk.

A common misconception is that efficacy and potency mean the same thing. They do not. Potency refers to the dose required for a given effect (a more potent medicine requires a smaller dose), while efficacy refers to the maximum effect achievable. Medicine A may be more potent than medicine B (effective at lower doses) but have the same maximum efficacy. Another misconception is that higher efficacy is always better - for some indications, like partial opioid agonists in addiction medicine, a ceiling on effect is the therapeutic advantage.

Prescribers consider both efficacy and potency when titrating doses, choosing among similar agents, and managing patient expectations. The dose-response curve in clinical pharmacology - particularly the maximum effect plateau (Emax) and the half-maximal effective dose (ED50) - formalizes these concepts.